Exclusive Growth Drivers

• Medicare Coverage

  • 4,000 – 8,000 patient opportunity over 3+ years

• Lowest rate of Neutralizing Antibodies

• Early Stage MS
  • 5,000 – 7,500 patient opportunity over the next few years

Previous slide

Next slide

Back to first slide

View graphic version